Skip to main content
Clinical Trials/CTRI/2011/09/002022
CTRI/2011/09/002022RecruitingPhase 4

Treatment of Early Neuropathy in Leprosy (TENLEP). Trial 1-randomized , double-blind, placebo -controlled trial to determine whether steroid treatment of early sub clinical nerve function impairment (NFI) would benefit patients in terms of the prevention of clinical sensory or motor function impairment. - TENLEP

Royal Tropical Institute KIT0 sites790 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor
Enrollment
790

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • All newly detected leprosy patients

Exclusion Criteria

  • 1) Any leprosy patient with single lesion on the trunk as the only sign of leprosy
  • 2) Any patient over 60 or under 15 on the basis of legal document
  • 3) Women with known pregnancy at the time of diagnosis
  • 4) People with known other conditions that may affect the peripheral nervous system (e.g. diabetes, alcohol abuse, HIV/Aids, carpel tunnel syndrome , nerve injuries) through specific history talking DM test, PICT for HIV, liver function tests.
  • 5) Any patient refusing informed consent.
  • 6) Any patient for whom full dose of steroid would be indicated for reasons other than recent nerve function impairment.

Investigators

Sponsor
Royal Tropical Institute KIT

Similar Trials